Press Releases

Release year: 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Release Tag:

December 10, 2012
Genetic Technologies Appoints Chief Executive Officer and Non-Executive Director

November 29, 2012
Genetic Technologies Provides Update on Board and Management Changes

November 20, 2012
Sunshine Heart Receives Unconditional FDA Approval for C-Pulse(R) System's U.S. Pivotal Trial

November 14, 2012
Biota Pharmaceuticals Announces Appointment of New Executive Officers

November 08, 2012
Sunshine Heart Announces 3Q12 Financial Results

November 08, 2012
Sunshine Heart to Present at Upcoming Investor Conferences

November 07, 2012
Biota Receives $4.2m R&D Tax Credit

October 23, 2012
Biota Announces Shareholder Approval of Merger With Nabi Pharmaceuticals

October 23, 2012
Sunshine Heart Receives 2012 Frost & Sullivan North American Heart Failure Treatment New Product Innovation Award for C-Pulse(R)

October 23, 2012
Biota Announces Approval of Definitive Merger Agreement by Nabi Shareholders

October 18, 2012
Sunshine Heart's Feasibility Study Data to Be Presented at 2012 Transcatheter Cardiovascular Therapeutics Conference

October 15, 2012
Genetic Technologies Files Patent Infringement Suits Against Multiple Alleged Infringers in USA

October 11, 2012
Benitec Announces Acquisition of Tacere Therapeutics and Phase I/II Ready Hepatitis C (HCV) Program

October 01, 2012
Audeo Oncology Announces New Board Appointments

October 01, 2012
Sunshine Heart Announces Conditional Approval of IDE From the FDA for C-Pulse(R) Heart Assist System

September 27, 2012
Vital Therapies, Inc. Announces First Closing of $76 Million Staged Financing to Fund Phase 3 Pivotal Clinical Trials of ELAD(R) in USA and EU

September 25, 2012
Genetic Technologies Announces BREVAGen(TM) Attains Clearance for Sale Into Florida

September 18, 2012
Biota and Nabi Announce Revised Merger Terms

September 13, 2012
Sunshine Heart Appoints John Erb to Chairman of the Board

September 13, 2012
Genetic Technologies Announces Key Managerial Appointment

August 30, 2012
Sunshine Heart Submits Investigational Device Exemption to FDA for C-Pulse(R) System Pivotal Trial

August 30, 2012
Genetic Technologies Files Patent Infringement Suit Against Reproductive Genetics Institute Inc. in USA

August 22, 2012
Biota Announces Inavir Achieves Primary Endpoint in Phase III Prevention Study

August 15, 2012
Sunshine Heart Announces Closing of Public Offering of Common Stock

August 10, 2012
Sunshine Heart Announces $20.125M Public Raise

August 10, 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs

August 09, 2012
Biota Shareholders Meeting on Proposed Merger With Nabi

August 08, 2012
Genetic Technologies Receives CE Mark Approval for BREVAGen(TM)

August 06, 2012
Sunshine Heart Announces Conditional Approval From FDA for Its Next Generation C-Pulse(R) System Driver

July 30, 2012
Sunshine Heart Announces 2Q12 Financial Results

July 26, 2012
Genetic Technologies Announces BREVAGen(TM) Cleared for Sale in California

July 25, 2012
Sunshine Heart Announces CE Mark for C-Pulse(R) Heart Assist System

July 24, 2012
Genetic Technologies Appoints Mr. Greg Brown as Director

July 23, 2012
Sunshine Heart Announces First Patient Reaches Two-Year Follow-Up Mark for C-Pulse(R) Heart Assist System

July 09, 2012
Audeo Oncology, Inc. Files Registration Statement for Proposed Initial Public Offering

June 07, 2012
Sunshine Heart Receives Health Canada Approval to Modify Its Ongoing Investigational Study to Use the Next Generation C-Pulse(R) System Driver

June 04, 2012
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM(R) (Bendamustine) in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

May 31, 2012
Single Center Data From C-Pulse(R) Feasibility Trial in Patients With Moderate to Severe Heart Failure to Be Presented at the 2012 ISMICS Annual Meeting

May 22, 2012
Genetic Technologies Provides BREVAGen(TM) Sales and Reimbursement Update

May 17, 2012
Neuren Holds Pre-IND Meeting on Proposed Rett Syndrome Clinical Trials With FDA

May 11, 2012
Biota Announces Inavir(R) Royalty Results for Q312 and Phase III Prevention Study Update

May 10, 2012
Sunshine Heart Announces 1Q12 Financial Results

May 09, 2012
Genetic Technologies Executes Settlement and License Agreement With GeneSeek Inc.

April 23, 2012
Biota and Nabi Announce Proposed Merger

April 13, 2012
Break-Through Invention for Treating Cancer -- Australian Biotech Company Completes Round 1 Funding

April 13, 2012
Genetic Technologies' Subsidiary Update

March 28, 2012
Biota Announces Positive Phase IIb Data for Asthmatic Patients With Human Rhinovirus Infection (HRV)

March 14, 2012
Sunshine Heart Announces FDA Completes Review of C-Pulse(R) Feasibility Data

March 12, 2012
Sunshine Heart Provides FAQ Regarding Transmutation of CDIs to Common Stock

March 08, 2012
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial and Operational Results

March 06, 2012
Threshold Pharmaceuticals Announces Oral Presentation on TH-302 Clinical Study at the 2012 AACR Annual Meeting

February 29, 2012
Genetic Technologies Provides Update on U.S. and Australian Gene Patenting Litigation, Case Law and Legislation

February 28, 2012
Alchemia to Present at the Cowen Health Care Conference

February 27, 2012
Genetic Technologies Announces Financial Results for Half-Year Ended 31 December 2011

February 24, 2012
Threshold Pharmaceuticals to Present at the Cowen Health Care Conference

February 21, 2012
Genetic Technologies Successfully Concludes Second Patent Infringement Suit in USA

February 21, 2012
Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic Cancer

February 17, 2012
Threshold Pharmaceuticals Appoints Dr. Tillman Pearce as Chief Medical Officer

February 16, 2012
Sunshine Heart Announces NASDAQ Listing

February 16, 2012
Genetic Technologies Receives CLIA Certificate of Compliance From Centers for Medicare and MedicAid Services, USA

February 15, 2012
Biota Announces Financial Results for First Half of Fiscal 2012

February 06, 2012
Genetic Technologies Executes Settlement and License Agreement With Eurofins STA Laboratories, Inc.

February 03, 2012
Threshold Pharmaceuticals and Merck KGaA Announce Global Agreement to Co-Develop and Commercialize Phase 3 Hypoxia-Targeted Drug TH-302

January 31, 2012
Genetic Technologies Files Quarterly Activities Report and ASX Appendix 4C for Quarter Ended December 31, 2011

January 04, 2012
Phylogica Licenses Technology to Janssen Biotech, Inc.

January 04, 2012
Alchemia Recruits First Patient to Pivotal Phase III Clinical Trial of HA-Irinotecan in Metastatic Colorectal Cancer